Cadrenal Therapeutics, Inc. (CVKD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Cadrenal Therapeutics reported revenue of $0. Net income was -$13.2M, or -$6.64 per diluted share. Operating activities generated -$12.6M of cash, leaving -$12.6M of free cash flow. At fiscal year end, Cadrenal Therapeutics held $4.3M in total assets against $1.6M in total liabilities, including $4.0M of cash and equivalents.
Open the full interactive Cadrenal Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Cadrenal Therapeutics Key Stats
| Share Price | $1.00 |
|---|---|
| Market Cap | $2.9M |
| 52-Week Range | $0.87 – $14.14 |
| Shares Outstanding | 2.9 million (basic, 2026 Q2) |
Cadrenal Therapeutics Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Goods Sold | $220,095 | — | — |
| Gross Profit | -$220,095 | — | — |
| Operating Income | -$7.6M | -$11.0M | -$13.5M |
| Pre-Tax Income | -$8.4M | -$10.7M | -$13.2M |
| Net Income | -$8.4M | -$10.7M | -$13.2M |
| Diluted EPS | -$9.30 | -$8.73 | -$6.64 |
Cadrenal Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$2.7M | -$3.0M | -$2.5M | -$3.3M |
| Diluted EPS | -$1.31 | -$1.52 | -$1.04 | -$1.14 |
Cadrenal Therapeutics Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $8.4M | $10.0M | $4.0M |
| Current Assets | $8.5M | $10.1M | $4.3M |
| Total Assets | $8.5M | $10.1M | $4.3M |
| Current Liabilities | $826,875 | $2.7M | $1.6M |
| Total Liabilities | $826,875 | $2.7M | $1.6M |
| Shareholders' Equity | $7.7M | $7.4M | $2.7M |
Cadrenal Therapeutics Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$3.5M | -$7.4M | -$12.6M |
| Cash From Investing | -$3,254 | -$6,537 | -$5,104 |
| Cash From Financing | $11.9M | $9.0M | $6.6M |
| Free Cash Flow | -$3.5M | -$7.4M | -$12.6M |
Figures from Cadrenal Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cadrenal Therapeutics financials page for every line item.
Cadrenal Therapeutics Company Profile
| Ticker | CVKD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Ponte Vedra, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001937993 |
Frequently Asked Questions
What was Cadrenal Therapeutics' revenue in fiscal 2025?
Cadrenal Therapeutics (CVKD) reported revenue of $0 for fiscal 2025.
What is Cadrenal Therapeutics' annual revenue history?
Cadrenal Therapeutics' annual revenue by fiscal year: 2023: $0; 2024: $0; 2025: $0.
What was Cadrenal Therapeutics' net income in fiscal 2025?
Cadrenal Therapeutics reported net income of -$13.2M for fiscal 2025.
What was Cadrenal Therapeutics' earnings per share (EPS) in fiscal 2025?
Cadrenal Therapeutics' diluted EPS was -$6.64 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cadrenal Therapeutics generate in fiscal 2025?
Cadrenal Therapeutics generated -$12.6M of free cash flow in fiscal 2025.
What was Cadrenal Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cadrenal Therapeutics reported revenue of $0.
How many shares of Cadrenal Therapeutics are outstanding?
Cadrenal Therapeutics reported a weighted average of 2.9 million basic shares outstanding in 2026 Q2.
What is Cadrenal Therapeutics' market cap?
Based on its latest closing price, Cadrenal Therapeutics (CVKD) has a market capitalization of about $2.9M.
When does Cadrenal Therapeutics' fiscal year end?
Cadrenal Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Cadrenal Therapeutics headquartered?
Cadrenal Therapeutics lists its business address in Ponte Vedra, Florida in its SEC filings.